Discover Upgraded Genomind Professional PGx Testing!

Test upgrades for Genomind Professional PGx report has been launched on 24 April 2023.

All samples will receive :
Analysis of the two new statin genes
Reformatted report with dosing guidelines
Supplemental diagnosis pages

About ABCG2 & SLCO1B1 (New Statin Genes)

There are several identified pharmacogenetic variants that impact statin disposition and adverse events during therapy. These additional genes can assist in providing personalized dosing, assess impact of statin exposure and risk of musculoskeletal side effects (e.g., muscle pain, muscle weakness).

Below details the specific changes made and how the report sequence will be improved:

Gene Report Overview: One-page summary of PK and PD gene results and their clinical impact.

Gene Drug Associations: Medications grouped by drug classes with PK and PD gene associations. Includes abbreviated CPIC, FDA, and/or DPWG associations with links to full guidelines.

Pharmacokinetic and Pharmacodynamic Gene Variations: Genetic results and detailed clinical significance of each gene.

Diagnosis Summary Page(s): Visual plot of medications for a particular condition shifted based on patient’s genetic results.

Click here for samples of laboratory reports:

Genomind Full NeuroPsych Report
International Sample Report
Genomind Supplemental Diagnosis Report

For enquiries on the upgraded Genomind professional PGx test, feel free to reach out to our sales representative at [email protected] or call +65 98254866.